AXSOME THERAPEUTICS, INC. Business Acquisition, Pro Forma Net Income (Loss)
AXSOME THERAPEUTICS, INC. (AXSM) reported Business Acquisition, Pro Forma Net Income (Loss) of -$61.50 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2025-02-18
- AXSOME THERAPEUTICS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2023-03-31 was -$61.50K.
- AXSOME THERAPEUTICS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2022-12-31 was -$57.95K.
- AXSOME THERAPEUTICS, INC. business acquisition, pro forma net income (loss) for the quarter ending 2022-09-30 was -$45.29K.
- AXSOME THERAPEUTICS, INC. business acquisition, pro forma net income (loss) for fiscal 2022 was -$211.57K.
- AXSOME THERAPEUTICS, INC. business acquisition, pro forma net income (loss) for fiscal 2021 was -$283.83K.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2023-03-31 | -$61.50K 10-Q · filed 2023-05-09 | -$119.45K derived: sum of 2 quarters · filed 2025-02-18 | -$164.74K derived: sum of 3 quarters · filed 2025-02-18 | ||
| 2022-12-31 | -$57.95K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | -$103.24K derived: sum of 2 quarters · filed 2025-02-18 | -$211.57K 10-K · filed 2025-02-18 | -$283.83M 10-K · filed 2023-02-28 | |
| 2022-09-30 | -$45.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$153.63K 10-Q · filed 2023-11-06 | |||
| 2022-06-30 | -$108.33K 10-Q · filed 2023-08-07 | ||||
| 2021-12-31 | -$283.83K 10-K · filed 2024-02-23 | -$211.57M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |